Market Place
Sourcing Support
Albireo`s Bylvay (Odevixibat) Approved In Europe
05 Jul 2023 //
EMA
Ipsen completes acquisition of Albireo, expanding the scope of Rare Disease
02 Mar 2023 //
GLOBENEWSWIRE
Ipsen extends expiration date of tender offer for Albireo to 1 March 2023
22 Feb 2023 //
GLOBENEWSWIRE
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
14 Feb 2023 //
GLOBENEWSWIRE
Failed deal, bidding war paved the way for Ipsen`s $952M rare disease buyout
24 Jan 2023 //
ENDPTS
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease
09 Jan 2023 //
BUSINESSWIRE
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 Dec 2022 //
GLOBENEWSWIRE
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
19 Dec 2022 //
GLOBENEWSWIRE
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer
06 Dec 2022 //
GLOBENEWSWIRE
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Dec 2022 //
GLOBENEWSWIRE
Reimbursed Access to (odevixibat) Approved in France for Patients PFIC 1 & 2
30 Nov 2022 //
GLOBENEWSWIRE
Reimbursed Access to Bylvay Approved in France for Patients with PFIC 1 & 2
30 Nov 2022 //
GLOBENEWSWIRE
Albireo to Participate in Jefferies London Healthcare Conference
09 Nov 2022 //
GLOBENEWSWIRE
Albireo Reports Q3 2022 Financial Results and Business Update
08 Nov 2022 //
GLOBENEWSWIRE
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022
07 Nov 2022 //
GLOBENEWSWIRE
Albireo Announces 2022 SPARK Grant Winners
03 Nov 2022 //
GLOBENEWSWIRE
Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia
02 Nov 2022 //
GLOBENEWSWIRE
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
01 Nov 2022 //
GLOBENEWSWIRE
Albireo to Report Q3 2022 Financial Results on November 8, 2022
31 Oct 2022 //
GLOBENEWSWIRE
Mirum gains an edge over rival Albireo in pediatric liver disease
24 Oct 2022 //
FIERCEPHARMA
Mirum gets a leg up on Albireo in pediatric liver disease
24 Oct 2022 //
FIERCEPHARMA
Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® NASPGHAN
13 Oct 2022 //
GLOBENEWSWIRE
Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV)
12 Oct 2022 //
GLOBENEWSWIRE
Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay
12 Oct 2022 //
GLOBENEWSWIRE
Albireo`s Bylvay aces test in Alagille syndrome, setting for liver disease nod
11 Oct 2022 //
FIERCEPHARMA
Albireo to Showcase New Data at AASLD The Liver Meeting® 2022
05 Oct 2022 //
GLOBENEWSWIRE
Liver-focused startup nabs $115M in exchange for rare disease drug royalties
26 Sep 2022 //
ENDPTS
Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?
23 Sep 2022 //
NASDAQ
Albireo Announces $115 Million Royalty Monetization Agreement with Sagard
22 Sep 2022 //
GLOBENEWSWIRE
Albireo to Participate in Guggenheim Nantucket Therapeutics Conference
20 Sep 2022 //
GLOBENEWSWIRE
Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat)
06 Sep 2022 //
GLOBENEWSWIRE
Albireo to Participate in Upcoming Investor Conferences
01 Sep 2022 //
GLOBENEWSWIRE
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 Aug 2022 //
GLOBENEWSWIRE
Medison Pharma Expands Partnership with Albireo to a Multi-Regional Agreement
16 Aug 2022 //
PRNEWSWIRE
Albireo Reports Q2 2022 Financial Results and Business Update
15 Aug 2022 //
GLOBENEWSWIRE
Albireo Appoints New Members to Board of Directors
10 Aug 2022 //
GLOBENEWSWIRE
Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference
03 Aug 2022 //
PRESS RELEASE
Albireo to Report Q2 2022 Financial Results on August 15, 2022
01 Aug 2022 //
GLOBENEWSWIRE
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26 Jul 2022 //
GLOBENEWSWIRE
Albireo to Present at the William Blair Biotech Focus Conference 2022
30 Jun 2022 //
GLOBENEWSWIRE
Albireo Presents New Bylvay (odevixibat) Data at Annual ESPGHAN Congress
24 Jun 2022 //
GLOBENEWSWIRE
Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases
23 Jun 2022 //
GLOBENEWSWIRE
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
07 Jun 2022 //
GLOBENEWSWIRE
Albireo to Participate at Upcoming Investor Conferences
02 Jun 2022 //
GLOBENEWSWIRE
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
19 May 2022 //
GLOBENEWSWIRE
Albireo Reports Q1 2022 Financial Results and Business Update
16 May 2022 //
GLOBENEWSWIRE
Albireo to Report Q1 2022 Financial Results on May 16
09 May 2022 //
GLOBENEWSWIRE
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM
29 Mar 2022 //
GLOBENEWSWIRE
Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update
01 Mar 2022 //
GLOBENEWSWIRE
NICE recommends Albireo’s Bylvay (odevixibat) for all PFIC types
23 Feb 2022 //
PHARMAFILE
Albireo to Publish PICTURE Study Highlighting the Caregiver Impact of PFIC
14 Feb 2022 //
GLOBENEWSWIRE
Albireo Announces Positive Topline Data from Phase 1 Study of A3907
16 Dec 2021 //
GLOBENEWSWIRE
Albireo CMO Horn exits 5 months after US, EU approvals
10 Dec 2021 //
FIERCEBIOTECH
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
02 Dec 2021 //
GLOBENEWSWIRE
Albireo to Present at Upcoming Investor Conferences
10 Nov 2021 //
GLOBENEWSWIRE
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines Bylvay™
12 Oct 2021 //
GLOBENEWSWIRE
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
15 Sep 2021 //
GLOBENEWSWIRE
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
08 Sep 2021 //
BIOSPACE
Albireo Sells Priority Review Voucher (PRV) for $105 Million
07 Sep 2021 //
GLOBENEWSWIRE
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™
18 Aug 2021 //
GLOBENEWSWIRE
